This document is an excerpt from the EUR-Lex website
Document 62015TB0269
Case T-269/15: Order of the General Court of 15 May 2019 — Novartis Europharm v Commission (Medicinal products for human use — Marketing authorisation for the medicinal product Vantobra — tobramycine — Withdrawal of the contested measure — Action which has become devoid of purpose — No need to adjudicate)
Case T-269/15: Order of the General Court of 15 May 2019 — Novartis Europharm v Commission (Medicinal products for human use — Marketing authorisation for the medicinal product Vantobra — tobramycine — Withdrawal of the contested measure — Action which has become devoid of purpose — No need to adjudicate)
Case T-269/15: Order of the General Court of 15 May 2019 — Novartis Europharm v Commission (Medicinal products for human use — Marketing authorisation for the medicinal product Vantobra — tobramycine — Withdrawal of the contested measure — Action which has become devoid of purpose — No need to adjudicate)
OJ C 246, 22.7.2019, p. 19–19
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
22.7.2019 |
EN |
Official Journal of the European Union |
C 246/19 |
Order of the General Court of 15 May 2019 — Novartis Europharm v Commission
(Case T-269/15) (1)
(Medicinal products for human use - Marketing authorisation for the medicinal product Vantobra - tobramycine - Withdrawal of the contested measure - Action which has become devoid of purpose - No need to adjudicate)
(2019/C 246/19)
Language of the case: English
Parties
Applicant: Novartis Europharm Ltd (Camberley, United Kingdom) (represented by: C. Schoonderbeek, lawyer)
Defendant: European Commission (represented by: M. Šimerdová, A. Sipos and K. Mifsud-Bonnici, acting as Agents)
Intervener in support of the defendant: Pari Pharma GmbH (Starnberg, Germany) (represented by: M. Epping and W. Rehmann, lawyers)
Re:
Application based on Article 263 TFEU seeking annulment of Commission Implementing Decision C(2015) 1977 final of 18 March 2015 granting marketing authorisation for the medicinal product for human use Vantobra — tobramycine, in accordance with Regulation No 726/2004 of the European Parliament and of the Council,
Operative part of the order
|
1. |
There is no longer any need to adjudicate on the present action. |
|
2. |
Novartis Europharm Ltd shall bear its own costs and pay those incurred by the European Commission. |
|
3. |
Pari Pharma GmbH shall bear its own costs. |